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ABSTRACT: Alpha-synuclein (SNCA) is crucial in
the pathogenesis of Parkinson’s disease (PD), yet muta-
tions in the SNCA gene are rare. Evidence for somatic
genetic variation in normal humans, also involving the
brain, is increasing, but its role in disease is unknown.
Somatic SNCA mutations, arising in early development
and leading to mosaicism, could contribute to PD
pathogenesis and yet be absent or undetectable in
DNA derived from peripheral lymphocytes. Such muta-
tions could underlie the widespread pathology in PD,
with the precise clinical outcome dependent on their
type and the timing and location of their occurrence.
We recently reported a novel SNCA mutation
(c.150T>G, p.H50Q) in PD brain-derived DNA. To deter-
mine if there was mosaicism for this, a PCR and cloning
strategy was used to take advantage of a nearby
heterozygous intronic polymorphism. No evidence of
mosaicism was found. High-resolution melting curve
analysis of SNCA coding exons, which was shown to
be sensitive enough to detect low proportions of 2
known mutations, did not reveal any further mutations
in DNA from 28 PD brain-derived samples. We outline
the grounds that make the somatic SNCA mutation hy-
pothesis consistent with genetic, embryological, and
pathological data. Further studies of brain-derived
DNA are warranted and should include DNA from
multiple regions and methods for detecting other types
of genomic variation. VC 2013 Movement Disorder Society
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Alpha-synuclein (SNCA), encoded by the SNCA
(PARK1) gene, is central to the pathogenesis of Par-
kinson’s disease (PD).1,2 It is the major component of
Lewy bodies. Misfolding into oligomers and fibrils is
believed to underlie its toxicity, although the precise
nature of the toxic species remains unclear. Three
SNCA missense mutations have been reported in pedi-
grees with autosomal dominant inheritance.3–5 We
recently identified the c.150T>G/p.H50Q mutation in
DNA derived from the brain of a single apparently
sporadic case of late-onset PD.6 Copy number varia-
tions (CNVs, duplications and triplications) have also
been described,7,8 and noncoding variation in SNCA
is a risk factor for sporadic PD.9 Several large studies
analyzing DNA from blood lymphocytes have not
found additional mutations, including 1 of more than
1900 mostly sporadic patients.10
Mutations occurring postzygotically are termed so-
matic and can lead to mosaicism (the presence of
more than 1 genetically distinct cell in a single orga-
nism).11 The number of cell divisions in normal devel-
opment has led to the suggestion that each gene may
mutate several times postzygotically, with the term
somatic evolutionary genomics used to refer to the
accumulation of genetic change within the cell lineage
of a single individual.12 Somatic mutations occurring
in early embryogenesis in a dividing cell whose prog-
eny will include neurons, derived from the ectoderm,
could contribute to PD, but they could be missed
when mesoderm-derived lymphocyte DNA is analyzed,
in which they might be absent or present at a level
below the 15%–30% resolution limit of Sanger
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sequencing.13–15 Low-level mosaicism could have been
missed even in the few small studies in which SNCA
was analyzed in PD brain-derived DNA, as the meth-
ods were not sensitive enough.16–18 Somatic mutation
has previously been suggested as a cause of sporadic
neurodegenerative disorders19,20 and was very recently
hypothesized as a possible explanation of phenotypi-
cally discordant LRRK2 monozygotic twins.21,22 In
Alzheimer’s disease, a case with mosaicism from so-
matic mutation of presenilin-1 was described, with
14% mutant DNA in the cortex.23 Hereditary spastic
paraplegia caused by mosaicism for a spastin mutation
has been reported.24 Very recently, a novel form of
neurodegeneration with brain iron accumulation has
been found to be a result of mutations in WDR45,
with a somatic origin in some cases.25 Mosaicism for
triplet-repeat neurodegenerative disorders from so-
matic mutation of the expanded repeat has been
described,26,27 including fragile X premutation syn-
drome, in which somatic instability in brain appears
more pronounced than in blood,28 and c9orf72 in
amyotrophic lateral sclerosis.29 Mosaicism for the
expanded repeat may be the cause of intrafamilial var-
iation in Friedreich’s ataxia30 and is associated with
onset age in Huntington’s disease.31 In the special case
of the mitochondrial genome, heteroplasmic somatic
DNA deletions and point mutations in the substantia
nigra (SN) are associated with PD.32–34
We therefore decided to test the hypothesis that
SNCA somatic coding mutations present in the brain
may contribute to PD by investigating the possibility
of mosaicism for the H50Q mutation, and by using
high-resolution melting curve (HRM) analysis for
detection of possible low-proportion mosaicism in PD
brain-derived DNA.
Patients and Methods
DNA from the brains of 28 patients with idiopathic
PD from the Queen Square Brain Bank was analyzed.
Patients had given informed consent for use of their
brains in research, and the study was approved by the
local ethics committee. The demographics and clinical
detail of this cohort are summarized in Supporting
Table 1. DNA was available from the SN and cerebel-
lum in 5 cases, from the cerebellum in 7 cases, and
from the caudate nucleus in 16 cases. The SN DNA
had been previously sequenced in all 5 of the cases in
which it was available, leading to the detection of the
c.150T>G/p.H50Q mutation in 1 case.6 HRM analy-
sis of PCR amplicons for all coding exons was per-
formed using Idaho Technology HRM mastermix,
amplicon melting on a Lightscanner (Idaho Technol-
ogy, Salt Lake City, UT) and melt curves analysis with
Call-IT 2.0 software. Further details and additional
primers used for subcloning are shown in Supporting
Table S1. HRM analysis is a robust and efficient
method for screening small PCR amplicons for
unknown mutations that relies on altered melting of
heteroduplexes. Sensitivity is >99% for heterozygous
point mutations and small insertions/deletions. In the
case of mosaicism, a 5%–10% proportion of mutant
DNA is detectable by HRM analysis,15 although
detection of mutation proportion as low as 0.5% has
been reported,35 making it highly suitable for screen-
ing for low-level mutations; the main limitation is the
ability to analyze only small PCR amplicons, ideally
150–250 base pairs long.15
Results
Because of the a priori very low likelihood of an
apparently sporadic late-onset PD case harboring a
novel heterozygous missense mutation, we considered
the possibility that the patient in whom we recently
detected the novel c.150T>G (p.H50Q) mutation in the
SN and cerebellum6 might have been a mosaic for a so-
matic mutation. Direct testing for the mutation in other
tissues or in brain regions other than the SN or cerebel-
lum was not possible, as no material was available. In-
heritance could not be investigated, as relatives could
not be traced. Mosaicism can be indirectly confirmed
by determining the phase of a mutation in relation to a
nearby heterozygous single-nucleotide polymorphism if
a third allelic combination is present.23 Sequencing a
PCR product including exon 3 but extending 430 bp
upstream into intron 2 revealed heterozygosity for a
known 5-base polymorphic insertion duplication
(c.122–133_122–129dupTTTTT, rs72240586). A per-
son heterozygous for both the c.150T>G exonic muta-
tion and the 5T intronic duplication should have only 2
allele combinations, with the T and G at position c.150
each in cis with 1 of the rs72240586 variants; the pres-
ence of a third allele combination would indicate mosa-
icism and prove a somatic event (Fig. 1A). SN and
cerebellar DNA was therefore amplified and subcloned
in 2 independent experiments each; restriction digestion
using BsgI (for which c.150T>G generates a restriction
site) of direct colony PCR products was used to differ-
entiate wild-type (wt) and mutant colonies. Sequencing
of mutant colony PCR products from the SN and cere-
bellum revealed c.150G to be in cis with the
rs72240586 duplication allele (Fig. 1B), whereas
sequencing of all wt colony PCR products from 1
experiment of each DNA source demonstrated c.150T
to be in cis with the reference (nonduplicated)
rs72240586 allele (Fig. 1C), with no colony PCR prod-
ucts showing c.150T in cis with the rs72240586 dupli-
cation allele (Fig. 1D). Therefore, there was no evidence
of mosaicism.
To detect any SNCA somatic mutations that might
be present at levels below the sensitivity of Sanger
P R O U K A K I S E T A L .
2 Movement Disorders, Vol. 00, No. 00, 2013
sequencing, we developed an HRM analysis protocol
for the coding exons (2–6). We first verified that all
known exon 3 mutations could be detected in the het-
erozygous state by performing HRM analysis on DNA
samples carrying known mutations (SN with
c.150T>G/p.H50Q and lymphocytes with c.157G>A/
p.A53T and c.136G>A/p.E46K), all of which were
differentiated from control DNA (Fig. 2). As our aim
was to detect somatic mutations at levels below 50%,
the lowest proportion detectable was determined by
HRM analysis of serial dilutions of genomic DNA car-
rying the H50Q and A53T mutations (for which
adequate DNA was available) with wt DNA. HRM
analysis against controls in triplicate revealed that mu-
tant DNA proportions of 12.5% and 2.5%, respec-
tively, were detectable (Fig. 3). All coding exons were
amplified and analyzed by HRM in all 28 samples,
but no shifts in melting curves signifying additional
mutations were detected.
Discussion
DNA sources for Somatic Mutation Studies
We found no evidence of mosaicism for H50Q
within the cerebellum and SN, but the possibility of a
somatic mutation arising very early in embryogenesis
and therefore being present in all brain cells, preclud-
ing detection of mosaicism within a single tissue,
could not be excluded.36,37 Detection of this mutation
in additional cases would help to prove an inherited
rather than a somatic origin. While this article was
under review, the same mutation was reported in a
FIG. 1. Determination of allele combinations at the rs72240586 polymorphic locus and c.150 (exon shown as light gray). A: Possible allele combina-
tions in heterozygosity and mosaicism. The third combination indicates somatic origin of the c.150T>G mutation on the chromosome carrying
rs72240586 allele B, with mosaicism evident, as both T and G are found in cis with allele B. B: Allele combination observed in chromosome without
c.150T>G mutation. C: Allele combination observed in chromosome with c.150T>G mutation. D: Hypothetical third combination (not observed),
which would have proven mosaicism by indicating that the mutation had arisen on the chromosome with the duplicated rs72240586 allele, but the
original wild-type allele in cis with the rs72240586 duplication allele was also present.
FIG. 2. HRM analysis of all known exon 3 mutations. A: Heterozygote c.157G>A (p.A53T) and c.150T>G (p.H50Q) in duplicate are differentiated
from 3 controls in triplicate. B: c.136G>A (p.E46K) heterozygote in duplicate is differentiated from 2 controls in duplicate.
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Canadian familial patient, further supporting the con-
clusion that this was an inherited variant.38 We ana-
lyzed samples derived from different brain regions
using HRM, which has proven sensitivity for low-level
somatic mutations that could be missed by Sanger
sequencing, but did not find any to support our hy-
pothesis. The possibility that somatic mutations were
present in other regions could not be excluded. Care-
ful consideration needs to be given to the choice of
brain region for the detection of hypothesized somatic
mutations, although this may be limited by availabil-
ity, as in our case. The pathology of PD extends well
beyond the mesencephalon-derived SN, and even
regions affected early in its course are anatomically
and embryologically distant (the olfactory bulb arising
from the prosencephalon, the dorsal motor nucleus of
the vagus from the rhombencephalon, and enteric neu-
rons from the neural crest39). Although the orderly
progression described by Braak40 may explain this, we
propose that the widespread early distribution of PD
pathology could be partly explained by somatic muta-
tions arising by the third week of embryogenesis; this
would lead to neurons carrying the mutations found
in all 3 primary brain vesicles (prosencephalon, mesen-
cephalon, rhombencephalon) and the neural crest
(Fig. 4). In this case, use of any neuroectodermal tissue
could allow detection of relevant somatic mutations,
and brain regions in which neurons are resistant to
the disease pathology (eg cerebellum in PD) would
have the highest chance of detection of surviving neu-
rons carrying these mutations. It is important to
emphasize that, although it may seem counterintuitive,
mutations occurring before the 3 germ layers split
could lead to mosaicism not restricted to the ecto-
derm, as already demonstrated in the case of the Alz-
heimer’s mosaic, with an 8% mutation proportion in
the mesoderm-derived blood, which was initially not
detected23; such very early somatic mutations could
therefore be detected in blood if sufficiently sensitive
methods were used.
Pathology Variants, Mosaicism Pattern, and
Spread
As variations from the Braak model are well estab-
lished in a proportion of PD cases,41 we suggest that
the precise pathology pattern in Lewy body diseases
could depend on the distribution of neurons derived
from the precursor that acquired the mutation. This is
FIG. 3. HRM analysis of DNA-carrying mutations, undiluted and diluted with control DNA, against control DNA in triplicate. The percentage of mu-
tant DNA in each PCR template is shown. Left, c.157G>A (p.A53T), undiluted mutant percentage 50%, differentiated at 2.5% (1 in 20 dilution). Right,
c.150T>G (p.H50Q), undiluted mutant percentage 50%, differentiated at 12.5% (1 in 4 dilution), not clearly differentiated at 5%.
FIG. 4. Schematic view of nervous system embryological derivation,
with examples of somatic mutations affecting different cell populations
(A–E). A: Mutation present in a proportion of cells from all germ layers.
B: Mutation absent in nonectodermal tissues (eg, blood). C: Mutation
present in all neuroectodermal tissue, including autonomic nervous
system, but absent in skin. D: Mutation present throughout CNS. E:
Mutation restricted to neural crest–derived structures (eg, adrenal me-
dulla). As progenitor cell specification occurs very early, the diagram
indicates the spatial distributions but not necessarily the precise tim-
ing of mutations.
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consistent with reports of apparently multicentric early
SNCA pathology in some incidental Lewy body dis-
ease cases.42 The unexplained asymmetry in PD could
relate to an asymmetric, stochastic somatic mutation
burden. Lewy body diseases with distinct profiles,
such as pure autonomic failure that is accompanied by
hyposmia as severe as PD,43 would be a result of a
mosaic pattern that differs from PD. In an analogous
way, somatic mutations have been proposed as the
cause of patient-specific variations in light-chain depo-
sition in systemic light chain-amyloidosis.44 A contin-
uum of risk of PD and age of onset would be
dependent on the relative mutation load of an individ-
ual’s neural tissue, as suggested for neurodegenerative
disease in general.12 Inherited mutations would lead to
the highest risk and earliest onset; whereas somatic
mutations very early in neuroectodermal development
could lead to a similar situation, those arising later
and affecting fewer neurons would result in later-onset
disease, and those with the least neuronal involvement
could result in clinically silent incidental Lewy body
disease. This is consistent with the observation that, in
general, age of onset is earlier and severity greater in
those who have inherited a SNCA mutation than in
sporadic cases and would lead us to expect a higher
prevalence of somatic mutations and higher mutation
load in younger-onset cases. It is worth noting that
many structures derived from the neural crest (which
forms as the dorsal neural tube closes and whose
derivatives include the sensory ganglia, sympathetic
chain and preaortic ganglia, parasympathetic gastroin-
testinal ganglia, Schwann cells, adrenal medulla, and
salivary glands) demonstrate SNCA pathology45; in
the adrenal gland, pathology is seen in the medulla
and related nerve bundles, but not in the mesoderm-
derived cortex. Somatic mutations occurring late in
the neural crest lineage could underlie the occasional
reports of isolated Lewy body–like pathology in pe-
ripheral structures such as the adrenal medulla46 and
in heart and stellate ganglia.47
Somatic mutations occurring later in neurodevelop-
ment and therefore restricted to a small region could
modify protein conformation locally, and this could
still lead to spread by permissive templating48 and
prion-like propagation of pathology.49 The concept of
spread of neurodegenerative disease from a small
focus of cells with a somatic mutation has already
been proposed, with particular emphasis on amyotro-
phic lateral sclerosis.12,50 In this scenario, a negative
result in brain-derived DNA would not exclude an ini-
tiating somatic mutation, which would be extremely
difficult to detect, as neurons carrying it would be
among the first to die after triggering the pathogenic
process; a similar issue was discussed in relation to
mtDNA mutations, with SN neurons with high
mtDNA mutation levels likely to be lost early in the
disease course.34 It is clear that harboring a SNCA
mutation is not enough to lead to death of any type of
neuron, as even in cases with inherited mutations,
which all neurons carry, the distribution of pathology
is very specific.51 Selective vulnerability of neurons in
PD is determined by a number of properties,52 and the
eventual pathological effect of a somatic mutation
would depend on the biological effect of the mutation
per se, the pattern of mosaicism and mutation load,
selective neuronal vulnerability, and patterns of inter-
neuronal propagation that may occur.
Mosaicism for Other Types of Genomic
Variants
We have focused our pilot work on attempting to
detect small SNCA coding mutations, yet mosaicism
for other types of genomic variation also merits con-
sideration. CNV mosaicism is widespread,53 estab-
lished very early in development,54 and present in
normal brain.55 It is notable that a study of monozy-
gotic twins discordant for PD or related phenotypes
detected several copy number variations of somatic or-
igin between cotwins of each pair, but as the DNA
was derived from blood, no conclusion could be made
on their pathogenicity.56 Somatic CNVs arise more
frequently in chromosomal fragile sites,57,58 which
include the regions where SNCA59 and PARK260 re-
side. CNVs can be induced by DNA “replication
stress,”57 which is likely in the rapidly dividing neuro-
nal precursors.61 Mosaicism for aneuploidy (gains or
losses of whole chromosomes) is very common in
humans.62 Aneuploidy is common in neural progenitor
cells, from which the cerebral cortex is derived, and a
significant proportion appear to survive into adult-
hood as postmitotic neurons,63 with aneuploidy esti-
mated in 10% of human brain cells.64 Aneuploidy for
chromosome 21 is more common in Alzheimer’s dis-
ease brains than in controls,64 and hyperploid neurons
in general are selectively vulnerable.65 Finally, the
LINE-1 retrotransposon constitutes around 20% of
the human genome, and abundant LINE-1 somatic
rearrangements by a “copy-and-paste” mechanism
arising specifically in neuronal precursors in embry-
onic development already indicate significant acquired
variability in normal human neuronal genomes.66,67
No data on relevance to disease are available, but
occasional somatic LINE-1 insertions were reported in
healthy control brains in both SNCA and PARK2,66
confirming that these genes are susceptible to such
disruption.
A Developmental and Evolutionary
Perspective
Early somatic mutations leading to later neurode-
generation would be consistent with the “high initial
load hypothesis” of the aging process, which proposes
that initial damage of living organisms in fetal or early
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life may be responsible for later-onset degenerative
disease.68 Even mtDNA mutations, generally consid-
ered to be acquired later in life, could arise in early
development.69 Early somatic mutations may not,
however, simply be accidents predisposing to later dis-
ease but could provide the basis for selection within
an organism.11,70 This could be particularly relevant
to selection of neuronal precursors and neurons that
survive the massive apoptotic programmed cell death
in early central nervous system development,71 which
affects most neuronal populations, including dopami-
nergic neurons in the SN at the time of maximal com-
petition for synaptic contact.72 A role for genetic
variation (“chromosomal programming”) in the devel-
opment of the nervous system, in a manner analogous
to the immune system, was first suggested in 1967.73
Very recent data demonstrate that extreme aneuploidy
is selected against in neurodevelopment.74 Multiple
lines of evidence point to an important developmental
role for SNCA, first in neuronal differentiation and
later in synaptogenesis,75,76 with prominent perikaryal
expression of SNCA in early development in the same
neuronal groups later affected in PD.77 Therefore, we
can speculate that certain somatic SNCA variants
could be beneficial to neurons or their precursors in
early development, undergoing positive selection
within the organism, with PD a much later adverse
consequence. As PD commonly develops past child-
bearing age, the mechanism that allows these early so-
matic changes would not be selected against and could
indeed be favored by evolution if it allowed more
genomic variation to provide a wider pool for selec-
tion of robust developing neurons. A similar explana-
tion has already been put forward to account for
LINE-1 mosaicism, suggesting that it favors generation
of neuronal diversity, despite the possible risk of
inducing neurological disease.78
Conclusions
The investigation of the potential contribution of so-
matic mutation to sporadic neurodegenerative disor-
ders is in its infancy. Further large-scale analysis of
brain DNA is warranted to test the hypothesis that so-
matic mutations of SNCA, or indeed other genes, may
contribute to sporadic PD. The HRM protocol we
have developed could be used for detecting low-
proportion somatic coding SNCA mutations, but
although HRM sensitivity can be improved even fur-
ther to 0.1%–1% by the use of a PCR modification
that preferentially amplifies low-level mutants,79 the
falling cost and increasing versatility of next-genera-
tion sequencing should also allow its use for detection
of low-proportion somatic mutations by using very
high depth of coverage for targeted genomic regions;
this was very recently demonstrated for selected mito-
chondrial80 and nuclear81,82 genes. Additional
techniques need to be considered for detection of
larger variants, such as FISH for aneuploidy; custom
CGH arrays can improve sensitivity for mosaic
CNVs,83 but the improving detection of CNVs in
next-generation sequencing data and droplet digital
PCR sensitivity of 0.1%53 is likely to revolutionize
CNV mosaicism studies. Ideally, multiple brain
regions should be sampled, and other neuroectoderm-
derived tissues could be analyzed. Demonstration of
mosaicism for any mutations detected in brain would
preferably be confirmed by analysis of other tissues,
and their collection by research facilities should be
considered; conversely, clinicians should bear in mind
that the absence of a detectable mutation in blood
cannot exclude a somatic mutation.
Although we have not detected any evidence of so-
matic mutations in our pilot work, we believe that we
have provided strong grounds for considering a contri-
bution of somatic mutations in SNCA or other genes
to PD in at least a proportion of cases. If SNCA and
other PD genes are particularly susceptible to somatic
mutation and/or if certain deleterious somatic variants
paradoxically confer a selective developmental advant-
age to neuronal precursors or neurons, somatic muta-
tion could underlie a substantial proportion of PD and
other Lewy body-type pathology.
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